Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy

@article{Giles2010NilotinibIA,
  title={Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy},
  author={Francis J Giles and Elisabetta Abruzzese and Gianantonio Rosti and D Y Kim and Ravi Bhatia and Andr{\'e} Bosly and Stuart L Goldberg and Grace Li Shan Kam and Madan H. Jagasia and Włodzimierz Mendrek and Thomas Fischer and Thierry Facon and Ulrich D{\"u}nzinger and D. W. Marin and Martin Christian M{\"u}ller and Yaping Shou and Neil Gallagher and Richard A Larson and F-X Mahon and Michele Baccarani and J. C. Gal{\'a}n Cort{\'e}s and Hagop M Kantarjian},
  journal={Leukemia},
  year={2010},
  volume={24},
  pages={1299-1301}
}
Nilotinib is a highly selective Bcr–Abl inhibitor approved for imatinib-resistant chronic myeloid leukemia (CML). Nilotinib and dasatinib, a multi-targeted kinase inhibitor also approved for second-line therapy in CML, have different patterns of kinase selectivity, pharmacokinetics, and cell uptake and efflux properties, and thus patients may respond to one following failure of the other. An international phase II study of nilotinib was conducted in CML patients (39 chronic phase (CP), 21… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
36 Extracted Citations
10 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 36 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 10 references

Similar Papers

Loading similar papers…